About Spectrum Pharmaceuticals (NASDAQ:SPPI)
Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection for patients with B-cell non-Hodgkin's lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing POZIOTINIB for treating breast and lung cancer; ROLONTIS for chemotherapy-induced neutropenia; and QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. The company sells its drugs through group purchasing organizations, wholesalers, and directly in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SPPI
CUSIP84763A10
Phone702-835-6300
Debt
Debt-to-Equity RatioN/A
Current Ratio2.53%
Quick Ratio2.48%
Price-To-Earnings
Trailing P/E Ratio-17.26
Forward P/E Ratio-17.93
P/E GrowthN/A
Sales & Book Value
Annual Sales$128.37 million
Price / Sales14.78
Cash FlowN/A
Price / CashN/A
Book Value$3.49 per share
Price / Book5.29
Profitability
EPS (Most Recent Fiscal Year)($1.07)
Net Income$-91,240,000.00
Net Margins-70.66%
Return on Equity-30.68%
Return on Assets-18.40%
Miscellaneous
Employees215
Outstanding Shares102,710,000
Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions
What is Spectrum Pharmaceuticals' stock symbol?
Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."
How were Spectrum Pharmaceuticals' earnings last quarter?
Spectrum Pharmaceuticals (NASDAQ:SPPI) announced its quarterly earnings data on Tuesday, March, 6th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $0.04. The biotechnology company earned $28.57 million during the quarter, compared to analyst estimates of $33.18 million. Spectrum Pharmaceuticals had a negative net margin of 70.66% and a negative return on equity of 30.68%. The company's quarterly revenue was down 18.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.10) EPS. View Spectrum Pharmaceuticals' Earnings History.
What price target have analysts set for SPPI?
4 Wall Street analysts have issued twelve-month target prices for Spectrum Pharmaceuticals' stock. Their forecasts range from $25.00 to $33.00. On average, they expect Spectrum Pharmaceuticals' share price to reach $29.00 in the next year. View Analyst Ratings for Spectrum Pharmaceuticals.
Who are some of Spectrum Pharmaceuticals' key competitors?
Some companies that are related to Spectrum Pharmaceuticals include FibroGen (FGEN), GW Pharmaceuticals (GWPH), Advanced Accelerator Application (AAAP), Blueprint Medicines (BPMC), Ligand Pharmaceuticals (LGND), Array BioPharma (ARRY), Tesaro (TSRO), Ultragenyx Pharmaceutical (RARE), Emergent BioSolutions (EBS), Amicus Therapeutics (FOLD), Ascendis Pharma (ASND), Evotec A.G. (EVTCY), Clovis Oncology (CLVS), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Acadia Pharmaceuticals (ACAD), Akorn (AKRX) and Puma Biotechnology (PBYI).
Who are Spectrum Pharmaceuticals' key executives?
Spectrum Pharmaceuticals' management team includes the folowing people:
- Mr. Joseph W. Turgeon, Pres, CEO & Director (Age 60)
- Mr. Kurt A. Gustafson, Exec. VP, CFO & Principal Accounting Officer (Age 50)
- Mr. Thomas J. Riga, Chief Operating Officer
- Mr. Shivpreet Kapoor, VP of Strategic Planning & Investor Relations
- Mr. Keith McGahan, Sr. VP & Chief Legal Officer
Has Spectrum Pharmaceuticals been receiving favorable news coverage?
Media stories about SPPI stock have trended positive recently, Accern Sentiment Analysis reports. Accern rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Spectrum Pharmaceuticals earned a coverage optimism score of 0.25 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 47.45 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Spectrum Pharmaceuticals' major shareholders?
Spectrum Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include
SHROTRIYA RAJESH C MD
(5.92%). Company insiders that own Spectrum Pharmaceuticals stock include Joseph W Turgeon, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner and Thomas J Riga. View Institutional Ownership Trends for Spectrum Pharmaceuticals.
How do I buy shares of Spectrum Pharmaceuticals?
Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spectrum Pharmaceuticals' stock price today?
One share of SPPI stock can currently be purchased for approximately $18.47.
How big of a company is Spectrum Pharmaceuticals?
Spectrum Pharmaceuticals has a market capitalization of $1.94 billion and generates $128.37 million in revenue each year. The biotechnology company earns $-91,240,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Spectrum Pharmaceuticals employs 215 workers across the globe.
How can I contact Spectrum Pharmaceuticals?
Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]
MarketBeat Community Rating for Spectrum Pharmaceuticals (SPPI)
MarketBeat's community ratings are surveys of what our community members think about Spectrum Pharmaceuticals and other stocks. Vote "Outperform" if you believe SPPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPPI will underperform the S&P 500 over the long term. You may vote once every thirty days.
Spectrum Pharmaceuticals (NASDAQ:SPPI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Spectrum Pharmaceuticals in the last 12 months. Their average twelve-month price target is $29.00, suggesting that the stock has a possible upside of 57.01%. The high price target for SPPI is $33.00 and the low price target for SPPI is $25.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $29.00 | $29.00 | $24.60 | $24.25 |
| Price Target Upside: | 57.01% upside | 31.82% upside | 29.20% upside | 28.31% upside |
Spectrum Pharmaceuticals (NASDAQ:SPPI) Consensus Price Target History
Spectrum Pharmaceuticals (NASDAQ:SPPI) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
Spectrum Pharmaceuticals (NASDAQ:SPPI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 12/11/2012 | special | $0.15 | | 12/18/2012 | 12/20/2012 | 12/28/2012 |
(Data available from 1/1/2013 forward)
Spectrum Pharmaceuticals (NASDAQ SPPI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 13.33%
Institutional Ownership Percentage: 77.32%
Spectrum Pharmaceuticals (NASDAQ SPPI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/18/2018 | Rajesh C Md Shrotriya | Director | Sell | 90,000 | $19.00 | $1,710,000.00 | 200,652 |  |
| 4/17/2018 | Joseph W Turgeon | CEO | Sell | 11,565 | $19.00 | $219,735.00 | 316,509 | |
| 4/16/2018 | Rajesh C Md Shrotriya | Director | Sell | 30,000 | $18.72 | $561,600.00 | 200,652 | |
| 4/16/2018 | Thomas J Riga | COO | Sell | 3,900 | $18.60 | $72,540.00 | 254,694 | |
| 4/13/2018 | Rajesh C Md Shrotriya | Director | Sell | 30,000 | $19.93 | $597,900.00 | 200,652 | |
| 4/11/2018 | Rajesh C Md Shrotriya | Director | Sell | 30,000 | $20.30 | $609,000.00 | 200,652 | |
| 4/9/2018 | Rajesh C Md Shrotriya | Director | Sell | 12,300 | $15.01 | $184,623.00 | 200,652 | |
| 4/6/2018 | Rajesh C Md Shrotriya | Director | Sell | 3,686 | $15.00 | $55,290.00 | 200,652 | |
| 4/4/2018 | Rajesh C Md Shrotriya | Director | Sell | 30,000 | $15.01 | $450,300.00 | 200,652 | |
| 4/2/2018 | Rajesh C Md Shrotriya | Director | Sell | 60,000 | $15.90 | $954,000.00 | 200,652 | |
| 4/2/2018 | Thomas J Riga | COO | Sell | 1,948 | $15.58 | $30,349.84 | 256,452 | |
| 3/28/2018 | Joseph W Turgeon | CEO | Sell | 4,810 | $16.40 | $78,884.00 | 328,074 | |
| 3/28/2018 | Kurt A Gustafson | CFO | Sell | 4,350 | $16.35 | $71,122.50 | 187,193 | |
| 3/28/2018 | Rajesh C Md Shrotriya | Director | Sell | 90,000 | $16.88 | $1,519,200.00 | 200,652 | |
| 3/26/2018 | Kurt A Gustafson | CFO | Sell | 1,300 | $17.38 | $22,594.00 | 191,543 | |
| 3/26/2018 | Rajesh C Md Shrotriya | Director | Sell | 30,000 | $17.34 | $520,200.00 | 200,652 | |
| 3/26/2018 | Thomas J Riga | COO | Sell | 220 | $17.41 | $3,830.20 | 251,476 | |
| 3/22/2018 | Joseph W Turgeon | CEO | Sell | 3,100 | $18.17 | $56,327.00 | 332,884 | |
| 3/22/2018 | Kurt A Gustafson | CFO | Sell | 2,640 | $18.13 | $47,863.20 | 192,843 | |
| 3/21/2018 | Stuart Mitchell Krassner | Director | Sell | 4,200 | $18.64 | $78,288.00 | 83,257 | |
| 2/5/2013 | Anthony E Maida III | Director | Sell | 5,000 | $12.25 | $61,250.00 | | |
| 11/12/2012 | Joseph Kenneth Keller | COO | Buy | 10,000 | $10.95 | $109,500.00 | | |
| 11/1/2012 | Anthony E Maida III | Director | Sell | 5,000 | $11.09 | $55,450.00 | | |
| 9/4/2012 | Anthony E Maida III | Director | Sell | 5,000 | $12.01 | $60,050.00 | | |
(Data available from 1/1/2013 forward)
Spectrum Pharmaceuticals (NASDAQ SPPI) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Zacks: Analysts Anticipate Spectrum Pharmaceuticals (SPPI) Will Announce Quarterly Sales of $26.10 Million
www.americanbankingnews.com - April 20 at 1:06 AM |
 | Spectrum Pharma (SPPI) Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers
www.streetinsider.com - April 19 at 8:13 AM |
| Brokerages Anticipate Spectrum Pharmaceuticals (SPPI) to Post -$0.24 EPS
www.americanbankingnews.com - April 18 at 11:22 PM |
| Spectrum Pharmaceuticals (SPPI) CEO Sells $219,735.00 in Stock
www.americanbankingnews.com - April 18 at 7:46 PM |
| Spectrum Pharmaceuticals (SPPI) Director Rajesh C. Md Shrotriya Sells 30,000 Shares
www.americanbankingnews.com - April 18 at 7:29 PM |
| Rajesh C. Md Shrotriya Sells 90,000 Shares of Spectrum Pharmaceuticals (SPPI) Stock
www.americanbankingnews.com - April 18 at 7:16 PM |
 | Spectrum Pharmaceuticals: What To Expect From This Powerful Grower
seekingalpha.com - April 18 at 8:15 AM |
| Thomas J. Riga Sells 3,900 Shares of Spectrum Pharmaceuticals (SPPI) Stock
www.americanbankingnews.com - April 17 at 7:28 PM |
 | Spectrum Pharmaceuticals Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers at the American ...
www.businesswire.com - April 17 at 5:56 PM |
 | Spectrum Pharmaceuticals Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers at the American Association for Cancer Research (AACR) in Chicago
finance.yahoo.com - April 17 at 5:56 PM |
| Spectrum Pharmaceuticals (SPPI) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 16 at 1:19 PM |
| Spectrum Pharmaceuticals (SPPI) Lowered to "Buy" at BidaskClub
www.americanbankingnews.com - April 14 at 9:13 PM |
| Spectrum Pharmaceuticals (SPPI) Director Sells $597,900.00 in Stock
www.americanbankingnews.com - April 13 at 7:13 PM |
| Rajesh C. Md Shrotriya Sells 30,000 Shares of Spectrum Pharmaceuticals (SPPI) Stock
www.americanbankingnews.com - April 13 at 7:13 PM |
 | Wait for a Pullback Before Rolling the Dice on SPPI Stock
investorplace.com - April 12 at 9:25 PM |
| Form 4 SPECTRUM PHARMACEUTICALS For: Apr 06 Filed by: SHROTRIYA RAJESH C MD
www.streetinsider.com - April 12 at 8:33 AM |
| Implied Volatility Surging for Spectrum Pharmaceuticals (SPPI) Stock Options
finance.yahoo.com - April 12 at 8:33 AM |
| Spectrum Pharmaceuticals (SPPI) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 12 at 8:33 AM |
| Wired News – Spectrum Pharma Reported Update Data from MD Anderson’s Phase-2 Data Assessing Poziotinib in EGFR Exon 20 Mutant NSCLC Patients
finance.yahoo.com - April 12 at 8:33 AM |
| Spectrum Pharmaceuticals (SPPI) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 11 at 6:45 PM |
 | Spectrum Down Following Positive Cancer Drug Test
www.baystreet.ca - April 11 at 5:34 PM |
 | 7 Stocks To Watch For April 11, 2018
www.benzinga.com - April 11 at 8:28 AM |
| BioSci Rounds Report: Strong Data Catapulted Spectrum While Intercept Is Poised For Growth
seekingalpha.com - April 11 at 8:28 AM |
| Your Daily Pharma Scoop: vTv Therapeutics Plunges, Spectrum Provides Updated Data, Selecta Sees Pullback On Data
seekingalpha.com - April 11 at 8:28 AM |
| Today’s Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Tandem Diabetes Care
finance.yahoo.com - April 11 at 8:28 AM |
| Insider Selling: Spectrum Pharmaceuticals (SPPI) Director Sells 12,300 Shares of Stock
www.americanbankingnews.com - April 10 at 10:16 PM |
| Rajesh C. Md Shrotriya Sells 3,686 Shares of Spectrum Pharmaceuticals (SPPI) Stock
www.americanbankingnews.com - April 10 at 10:16 PM |
 | Spectrum Pharmaceuticals (SPPI) Is Up Sharply On Study Results
www.nasdaq.com - April 10 at 5:31 PM |
| Spectrum Pharmaceuticals (SPPI) Shares Cross Above 200 DMA
www.nasdaq.com - April 10 at 5:31 PM |
| Why Spectrum Pharmaceuticals, Inc. Is Soaring Today
finance.yahoo.com - April 10 at 5:31 PM |
| Why Sprint, Spectrum Pharmaceuticals, and NVIDIA Jumped Today
finance.yahoo.com - April 10 at 5:31 PM |
| Spectrum Pharmaceuticals (SPPI) PT Raised to $13.00 at Jefferies Group
www.americanbankingnews.com - April 8 at 8:05 PM |
| Spectrum Pharmaceuticals (SPPI) Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 4 at 9:30 AM |
| Spectrum Pharmaceuticals Target of Unusually Large Options Trading (SPPI)
www.americanbankingnews.com - April 4 at 6:52 AM |
 | CASI Pharmaceuticals To Present At The H.C. Wainwright Global Life Sciences Conference
www.bizjournals.com - April 3 at 8:19 AM |
| Spectrum Pharmaceuticals to Present Corporate Update at the H.C. Wainwright Global Life Sciences Conference on April 10th
finance.yahoo.com - April 3 at 8:19 AM |
| Today’s Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Insmed
finance.yahoo.com - April 3 at 8:19 AM |
| Spectrum Pharmaceuticals (SPPI) Expected to Post Quarterly Sales of $26.10 Million
www.americanbankingnews.com - April 3 at 2:08 AM |
| ValuEngine Upgrades Spectrum Pharmaceuticals (SPPI) to "Buy"
www.americanbankingnews.com - April 3 at 12:00 AM |
| Thomas J. Riga Sells 1,948 Shares of Spectrum Pharmaceuticals (SPPI) Stock
www.americanbankingnews.com - April 2 at 10:41 PM |
| Spectrum Pharmaceuticals (SPPI) Director Sells $954,000.00 in Stock
www.americanbankingnews.com - April 2 at 10:21 PM |
| Analysts Expect Spectrum Pharmaceuticals (SPPI) Will Announce Earnings of -$0.31 Per Share
www.americanbankingnews.com - April 1 at 11:26 PM |
| Spectrum Pharmaceuticals (SPPI) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 1 at 5:28 PM |
| Kurt A. Gustafson Sells 4,350 Shares of Spectrum Pharmaceuticals (SPPI) Stock
www.americanbankingnews.com - March 28 at 10:46 PM |
| Spectrum Pharmaceuticals (SPPI) CEO Sells $78,884.00 in Stock
www.americanbankingnews.com - March 28 at 10:46 PM |
| Insider Selling: Spectrum Pharmaceuticals (SPPI) Director Sells 30,000 Shares of Stock
www.americanbankingnews.com - March 28 at 10:32 PM |
| Spectrum Pharmaceuticals (SPPI) Director Rajesh C. Md Shrotriya Sells 90,000 Shares
www.americanbankingnews.com - March 28 at 10:31 PM |
| Kurt A. Gustafson Sells 1,300 Shares of Spectrum Pharmaceuticals (SPPI) Stock
www.americanbankingnews.com - March 27 at 11:14 PM |
| Spectrum Pharmaceuticals (SPPI) Stock Rating Lowered by TheStreet
www.americanbankingnews.com - March 24 at 12:28 AM |
| Spectrum Pharmaceuticals (SPPI) Director Sells $78,288.00 in Stock
www.americanbankingnews.com - March 23 at 7:32 PM |
Spectrum Pharmaceuticals (NASDAQ:SPPI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Spectrum Pharmaceuticals (NASDAQ:SPPI) Income Statement, Balance Sheet and Cash Flow Statement
Spectrum Pharmaceuticals (NASDAQ SPPI) Stock Chart for Sunday, April, 22, 2018
Loading chart…
